Division of Alcon Inc.
Latest From ESBATech AG
Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
Alcon, Novartis's ophthalmic business, has reported positive results from a Phase II study of RTH258, which it is developing to compete against Regeneron Pharmaceuticals' Eylea (aflibercept). RTH258 has already entered Phase III testing.
Drug Discovery Tools
- Drug Discovery Tools
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Alcon Inc.
- Senior Management
Dominik Escher, PhD, CEO
Martin Gertsch, CFO
David Urech, PhD, Head, R&D
- Contact Info
Phone: (41) 44 733-4900
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.